Annual Review of the 2022 San Antonio Breast Cancer Symposium
This program is designed to discuss the content presented at the 2022 San Antonio Breast Cancer Symposium held on December 6th through December 10th, 2022, in San Antonio, Texas. Topics surrounding experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease will be highlighted.
Physicians, researchers, advanced practice providers, nurses, and other health care professionals who work with individuals with breast cancer.
• Identify the most up to date findings in breast cancer clinical and translational research.
• Incorporate research findings to appropriately manage patients with breast cancer.
• Demonstrate understanding of the scientific findings in breast cancer research by demonstrating competence in the clinical setting.
The meeting is planned to be live and virtual at this time.
All individuals in a position to control the content of this education activity have disclosed all financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships for the individuals listed below have been mitigated:
Parul Barry, MD, FACRO
Grant.Research Support (ACRO New Practitioner Grant); Consultant (Elsevier Pathway); CE Speakers’ Bureau (Varian and OncLive)
Adam Brufsky MD, PhD, FACP
Consultant (AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, and Puma); Grant/Research Support (Agendia and Astrazeneca
Emilia Diego, MD
CE Speakers’ Bureau (Clinical Care Options Panel Speaker for CME)
Charles Geyer, MD, FACP
Grant/Research Support (Genentech/Roche, AstraZeneca, Daiichi Sankyo/Astra Zeneca, Abbvie); Consultant (Exact Sciences); Other (Travel, Accommodations, and Expenses (Abbvie, Genentech/Roche, Daiichi-Sankyo, AstraZeneca)
Kit Lu, MD
Consultant (Daichii Sankyo, AstraZeneca, SeaGen, Merck, Stemline, Gilead); Advisory board- Novartis, Pfizer, Biotheranostic, Macrogenetics
Dhaval Mehta, MD
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours.
Physician Assistant (AAPA)
The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
- 5.00 AAPA Category I CME
- 5.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 5.00 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 5.00 Attendance
We gratefully acknowledge support from the following exhibitors for this activity:
Amgen, AstraZeneca, Bayer, Breast Cancer Index, Cancer Bridges, Caris Life Sciences, Daiichi Sankyo, Inc., Foundation Medicine, Gilead Oncology, Lilly Oncology, Merck, Novartis Oncology, Pfizer Oncology, Rigel Pharmaceuticals, Sobi North America, and Tempus Labs, Inc.
Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by emailing firstname.lastname@example.org.
All cancellations must be sent via email to Amy DiMaggio at email@example.com Cancellations received before Wednesday, February 8, 2023 will be refunded in full. After Wednesday, February 8, 2023, no refunds will be made.
For more information, please contact Amy DiMaggio at firstname.lastname@example.org.